Otsuka’s Astex secures $515m Roche deal for cell-cycle breast cancer candidates
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.
Pharma & Biotech
Pharma & Biotech
Novartis acquires SNV4818 from Synnovation in $3bn deal to reclaim ground in mutant PI3Ka breast cancer space
Novartis acquires SNV4818, a next-gen mutant-selective PI3Ka inhibitor, for up to $3bn. What this means for the HR+/HER2- breast cancer market. Read now.